Last Updated on December 22, 2024 by The Health Master
USFDA Inspection
Granules India Limited, a leading pharmaceutical manufacturer, has achieved a significant milestone with its Unit V facility located in Anakapally, Visakhapatnam, India. The facility recently underwent a rigorous USFDA inspection and emerged with flying colors, receiving zero 483 observations.
This accomplishment signifies Granules India’s unwavering dedication to meeting the highest quality standards for Active Pharmaceutical Ingredients (APIs) and Formulations (FDs) across oncology and non-oncology product lines.
Understanding the Significance of the USFDA Inspection
The US Food and Drug Administration (USFDA) is a highly respected regulatory body that oversees the safety and efficacy of drugs in the United States.
A pre-approval inspection (PAI) is a critical step for pharmaceutical facilities seeking to export drugs to the US market.
During this inspection, USFDA inspectors meticulously evaluate a facility’s compliance with Current Good Manufacturing Practices (cGMP) regulations.
These regulations encompass a wide range of aspects, including:
- Quality control procedures
- Manufacturing processes
- Documentation practices
- Facility and equipment maintenance
A successful USFDA inspection with zero 483 observations indicates that the inspected facility has met all the USFDA’s cGMP requirements.
This achievement is a strong testament to Granules India’s commitment to excellence in pharmaceutical manufacturing.
Benefits of Granules India’s Flawless USFDA Inspection
Granules India’s success in the USFDA inspection presents several advantages:
- Enhanced Market Access: This approval paves the way for Granules India to expand its reach into the lucrative US market for oncology and non-oncology drugs.
- Stronger Reputation: A flawless USFDA inspection bolsters Granules India’s reputation as a reliable and high-quality pharmaceutical manufacturer.
- Increased Investor Confidence: This positive outcome can instill greater confidence among investors in Granules India’s future prospects.
Conclusion
Granules India’s Unit V facility’s exceptional outcome from the USFDA inspection is a noteworthy accomplishment.
This achievement underscores the company’s dedication to manufacturing high-quality pharmaceutical products that meet stringent international standards.
By prioritizing quality and compliance, Granules India is well-positioned to become a major player in the global pharmaceutical market.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA Inspection: At Strides Pharma with 2 observations
USFDA completes inspection at Aurobindo with 3 observations
USFDA issued Form 483 with 6 observations to Cipla
USFDA grants VAI classification to Granules India
USFDA issued Form 483 with 4 observations to Alembic Pharma
USFDA issues EIR to Torrent Pharma for Gujarat Plant
Antibiotic Meropenem 1 mg + EDTA Injection has no CDSCO approval
Drug alert: 66 out of 931 samples declared as NSQ in March 2024
Important Update: Diploma in Pharmacy Exit Exam Announced for 2022-24 Batch
Drug recall: Glenmark recalls 6,528 bottles of this BP drug
CDSCO approval granted for this game changer Eye Drop
FSSAI: Food Labelling and Display – Chapter-4
Rs 36 Lakh Worth of Pharma Raw Material stolen
Codeine Phosphate and its Regulations in India
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
